6
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: not found
      • Article: not found

      Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Related collections

          Author and article information

          Journal
          The Lancet Oncology
          The Lancet Oncology
          Elsevier BV
          14702045
          May 2016
          May 2016
          : 17
          : 5
          : 622-631
          Article
          10.1016/S1470-2045(15)00584-7
          5494693
          27049457
          © 2016

          Comments

          Comment on this article